$9.25
-0.03 (-0.32%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PHAT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
14 interventional · 1 observational · 11 with posted results
Held by 12 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, Point72 Asset Management, L.P., MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, +7 more) · FINRA short interest 8.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their OffspringNCT06660342observationalNumber of Participants with Major Congenital Malformations (MCMs) | — | Recruiting | Drug: Vonoprazan | Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Helicobacter Pylori Infection | 728 | Sep 2034 | ≤ 2,964 d | 2025-05-22 |
| A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 WeeksNCT07752407Percentage of Treated Heartburn Episodes Achieving Complete Relief at 2 Hours and Sustained Relief for 24 Hours up to Week 12Randomized · Double-masked · Treatment | Phase 3 | Not yet recruiting | Drug: Vonoprazan, Placebo | Symptomatic Non-erosive Gastroesophageal Reflux Disease | 500 | 2027-10-20 | in 427 d | 2026-08-07 |
| A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 WeeksNCT06851559Number of Participants at Week 12 Achieving Peak Esophageal Intraepithelial Eosinophil Count <15 eos/hpf.Randomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Vonoprazan, Placebo | Eosinophilic Esophagitis | 95 | Oct 2026 | ≤ 73 d | 2026-06-29 |
| A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy ParticipantsNCT06831344results2025-12-19Maximum Observed Drug Concentration (Cmax) of VonoprazanRandomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference) | Healthy Volunteers | 25 | 2025-04-05actual | — | 2025-12-19 |
| A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice DailyNCT06391177results2025-03-25Area Under Drug Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) Following the Morning Dose of Vonoprazan in Breast MilkNon-randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Vonoprazan | Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease, Helicobacter Pylori Infection | 15 | 2024-09-13actual | — | 2025-03-25 |
| A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux DiseaseNCT06106022results2024-12-19Maximum Drug Concentration at Steady-state (Cmax,ss) of VonoprazanRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Vonoprazan | Gastroesophageal Reflux Disease | 22 | 2024-04-16actual | — | 2024-12-19 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux DiseaseNCT05343364results2024-06-03Maximum Observed Drug Concentration at Steady State (Cmax-ss) of VonoprazanRandomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Vonoprazan | Gastroesophageal Reflux | 24 | 2023-05-30actual | — | 2025-04-23 |
| A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)NCT05195528results2023-12-29Percentage of Days Without Daytime or Nighttime HeartburnRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Vonoprazan, Placebo | Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn | 776 | 2022-11-21actual | — | 2023-12-29 |
| A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy ParticipantsNCT05366738results2024-03-29Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of VonoprazanRandomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Vonoprazan, Vonoprazan | Healthy Volunteers | 27 | 2022-07-01actual | — | 2024-03-29 |
| A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux DiseaseNCT04799158results2023-01-04Percentage of Evaluable Heartburn Episodes Completely Relieved Within 3 Hours and With No Further Heartburn Reported for 24 Hours After Taking Study DrugRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Vonoprazan, Placebo | Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn | 458 | 2021-12-16actual | — | 2023-01-04 |
| Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive EsophagitisNCT04124926results2022-07-29Healing Phase: Percentage of Participants Who Had Complete Healing of EE by Week 8Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Vonoprazan, Lansoprazole | Erosive Esophagitis | 1,027 | 2021-07-29actual | — | 2022-07-29 |
| Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy ParticipantsNCT04729101results2023-03-31Gastric pH >4 Holding Time Ratio (HTR): Percentage of Time Gastric pH Was Above 4 Over a 24-hour Monitoring Period Following Study Drug AdministrationRandomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Vonoprazan, Lansoprazole | Healthy Participants | 44 | 2021-06-12actual | — | 2023-03-31 |
| Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori InfectionNCT04167670results2022-04-05Percentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants Without a Clarithromycin- or Amoxicillin-resistant Strain of H Pylori at BaselineRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Vonoprazan, Amoxicillin, Clarithromycin, Lansoprazole | Helicobacter Pylori Infection | 1,046 | 2021-03-10actual | — | 2022-04-05 |
| Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy ParticipantsNCT04558216Area Under the Plasma Concentration Versus Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-t) of VonoprazanOpen-label · Basic science | Phase 1 | Withdrawnsponsor's stated reason: Withdrawn due to unavailability of rifampin for clinical trial use | Drug: Vonoprazan, Rifampin | Healthy Participants | 0 | 2021-02-07 | — | 2022-03-02 |
| Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy ParticipantsNCT04545944results2023-03-17Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of MidazolamOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Vonoprazan, Midazolam | Healthy Volunteers | 20 | 2020-11-13actual | — | 2023-03-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19